Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Unleashing the Power of Streptozocin: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Streptozocin: A Comprehensive Review on R&D Breakthroughs
28 September 2023
This article summarized the latest R&D progress of Streptozocin, the Mechanism of Action for Streptozocin, and the drug target R&D trends for Streptozocin.
Read →
What is ICF in Life Sciences?
"What" Series
2 min read
What is ICF in Life Sciences?
28 September 2023
ICF stands for Informed Consent Form, which is a document proof that each participant voluntarily participates in a certain experiment.
Read →
A Comprehensive Review of Stiripentol's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Stiripentol's R&D Innovations and Drug Target Mechanism
28 September 2023
This article summarized the latest R&D progress of Stiripentol, the Mechanism of Action for Stiripentol, and the drug target R&D trends for Stiripentol.
Read →
Inmagene created Celexor Bio, based on its anti-ILT7 mAb displaying enhanced pDC reduction capabilities
Latest Hotspot
3 min read
Inmagene created Celexor Bio, based on its anti-ILT7 mAb displaying enhanced pDC reduction capabilities
28 September 2023
Inmagene has established Celexor Bio, which is premised on its anti-ILT7 mAb that demonstrates improved pDC reduction capabilities.
Read →
Pharmaceutical Insights: Sintilimab's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Sintilimab's R&D Progress and its Mechanism of Action on Drug Target
28 September 2023
This article summarized the latest R&D progress of Sintilimab, the Mechanism of Action for Sintilimab, and the drug target R&D trends for Sintilimab.
Read →
What is Protocol in Life Sciences?
"What" Series
2 min read
What is Protocol in Life Sciences?
28 September 2023
A protocol outlines the experiment's context, theory, and intent, its design, methodology, and structure including statistical considerations, and the conditions for execution and completion.
Read →
Exploring Sargramostim's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring Sargramostim's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
28 September 2023
This article summarized the latest R&D progress of Sargramostim, the Mechanism of Action for Sargramostim, and the drug target R&D trends for Sargramostim.
Read →
The Phase 3 TROPION-Breast01 trial showed Datopotamab Deruxtecan significantly improved progression-free survival in patients with HR positive, HER2 low/negative breast cancer
Latest Hotspot
3 min read
The Phase 3 TROPION-Breast01 trial showed Datopotamab Deruxtecan significantly improved progression-free survival in patients with HR positive, HER2 low/negative breast cancer
28 September 2023
The Phase 3 TROPION-Breast01 trial showed that Datopotamab Deruxtecan significantly improved progression-free survival for patients with HR positive, HER2 low or negative breast cancer.
Read →
Decoding Rocuronium Bromide: A Comprehensive Study of its R&D Trends
Drug Insights
4 min read
Decoding Rocuronium Bromide: A Comprehensive Study of its R&D Trends
28 September 2023
This article summarized the latest R&D progress of Rocuronium Bromide, the Mechanism of Action for Rocuronium Bromide, and the drug target R&D trends for Rocuronium Bromide.
Read →
What is DSMB?
"What" Series
2 min read
What is DSMB?
28 September 2023
DSMB stands for Data Safety and Monitoring Board, an independent expert group established to safeguard the rights and needs of infants and young children participating in Phase III clinical trials.
Read →
Deep Scientific Insights on Ripretinib's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Ripretinib's R&D Progress, Mechanism of Action, and Drug Target
28 September 2023
This article summarized the latest R&D progress of Ripretinib, the Mechanism of Action for Ripretinib, and the drug target R&D trends for Ripretinib.
Read →
Antengene Declares Phase I Trial for ATG-031, an Anti-CD24 Monoclonal Antibody
Latest Hotspot
3 min read
Antengene Declares Phase I Trial for ATG-031, an Anti-CD24 Monoclonal Antibody
28 September 2023
Antengene Corp Ltd obtained approval from University of Texas MD Anderson Cancer Center's Institutional Review Board for a Phase I trial of its prime anti-CD24 antibody, ATG-031, focusing on advanced hematology and oncology solutions.
Read →